



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS

ANNUAL ACCOUNTS

for



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS

Org. no.
802428-5986

THE FINANCIAL YEAR 2020

IFPA Secretariat
Gustavslundsvägen 143
167 51 Bromma
SWEDEN

www.ifpa-pso.com
info@ifpa-pso.com
[@psoriasisIFPA](https://www.instagram.com/psoriasisIFPA)





Director's Declaration 2020

The purposes, for which the Federation is formed, are to advance efforts to lessen the suffering of people with psoriasis and psoriatic arthritis and to improve methods of treatment and research for finding the ultimate cause and cure of the disease. In order to realize its purposes, the Federation shall:

- a) Represent the interests of its member associations in international forums such as the World Health Organization, the World Congress of Dermatology and international psoriasis symposia. IFPA shall also in close cooperation with other relevant international organizations organize international conferences, symposia and other events related to psoriasis and psoriatic arthritis, notably the annual global World Psoriasis Day campaign.
- b) Provide advice and consultation on the problems associated with psoriasis and psoriatic arthritis to member organizations or other communities and organizations worldwide.
- c) Provide the basis for closer liaison and the free exchange of information among psoriasis organizations and related organizations worldwide.
- d) Encourage and assist the establishment of new national organizations of people with psoriasis and psoriatic arthritis.
- e) Contribute to the improvement of the quality of health and social life of people suffering from psoriasis and psoriatic arthritis.
- f) The Federation shall not supersede or contravene the autonomy of national or other member organizations.

Vision

Achieve a world without suffering from psoriasis and psoriatic arthritis.

Mission

Be the global psoriasis advocacy association, with a focus on empowering our members, improving living conditions for psoriasis patients, raising awareness and cooperating with fellow stakeholders.





Goals

IFPA's goals as an organization are to:

1. Empower national psoriasis organizations by uniting them, strengthening their work and acting as their global voice.
2. Improve patients' living conditions by advocating for correct diagnosis, universal access to treatment and less discrimination and stigmatization.
3. Raise psoriasis awareness through education, information and highlighting research results.
4. Cooperate with relevant psoriasis stakeholders, including medical and pharmaceutical actors.

Governance

IFPA is governed by the General Assembly (GA) of its Full Members. The meeting of the General Assembly is held every three years, with the next to be held in 2022.

In furtherance of the objectives of the Federation, the IFPA Board shall implement IFPA policies and management between official General Assembly meetings. The IFPA Board may also call an Extraordinary General Assembly meeting, either as a physical meeting or by postal/online vote, should any urgent amendments to or clarifications of the IFPA Constitution or Bylaws be deemed necessary.

In 2020 the IFPA Board had ten Board meetings, of which one physical and nine virtual meetings.

Secretariat

The IFPA Secretariat was further expanded in 2020, with the Manager Administration and Events position joining in January (with focus on administration, financials and events). In 2020 there was also a shift in leadership with the former Executive Director leaving office in September. The Board conducted an extensive search for new leadership with recruitment finished in September and Frida Dunger Johnsson joining as new Executive Director in November.

By end of year, the IFPA Secretariat consisted of the:

- Executive Director
- Manager Administration and Events
- Scientific Officer





INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS

- Communications Manager
- Program Officer – Advocacy and Policy
- Program Officer – Capacity Development
- Project Developer
- Scientific Coordinator, part of year.

The number of filled full-time staff positions at the Secretariat was 7,25.

Key organizational developments and activities

- **Advocacy and policy**
- **Science**
- **External meetings**
- **Members**
- **Capacity Development**
- **World Psoriasis Day – Be Informed**
- **COVID-19 response**
- **Communications**
- **World Psoriasis and Psoriatic Arthritis Conference 2021**
- **Corporate Partners**
- **Overall summary of 2020**
- **Administration report**

Advocacy and policy

The Global Psoriasis Coalition is IFPA’s advocacy body uniting representatives from medical societies, NGOs, the corporate sector, foundations and professional societies. By cooperating across borders, sectors and disease areas, the Global Psoriasis Coalition works to implement the recommendations outlined in the World Health Organization’s 2016 Report on Psoriasis. The Coalition takes action to improve the lives of millions of people living with psoriasis and psoriatic arthritis.

The Global Psoriasis Coalition convened twice in 2020, once in July and once December. Members of the Global Psoriasis Coalition worked together to produce a statement on COVID-19 highlighting the impact of the pandemic on people living with psoriatic disease and recommending strategies to mitigate its effects. The statement was published on the Global Psoriasis Coalition website for members to access. 2020 marked the end of the strategic cycle in which the Coalition’s primary objective was the inclusion of psoriasis in the NCD agenda. The Global Psoriasis Coalition began setting the new strategic plan for the next three years by forming a Policy Task Force. In addition, a revision of the governance was discussed within the newly formed Governance Task Force. The two Task Forces will conclude their work at the beginning of 2021 when the Global Psoriasis Coalition strategic plan is presented.





Together we will overcome

In early 2020, pandemic response became the major global health priority and many people with psoriatic disease experienced disturbing disruptions in their access to care. IFPA released a COVID-19 advocacy toolkit on June 12th. This guide outlines how patient groups can use the World Health Assembly Resolution on COVID-19 Response (June 2020) to advocate for people living with psoriasis and psoriatic arthritis during the pandemic. People living with chronic conditions must always be able to access adequate care, especially during an emergency. National pandemic response plans must include provisions for people living with chronic conditions.

Psoriatic Disease Response Index

The primary deliverable of the Global Psoriasis Coalition in 2020 was the Psoriatic Disease Response Index (known colloquially as “the Index”).

The Index is the first-ever effort to survey, quantify, and analyze health systems’ responses on an international scale. By identifying five enablers and five barriers, the Index provides practical, evidence-based recommendations for each government to improve psoriatic disease management. Analyses combined desk research with expert interviews in the five countries: France, Denmark, Germany, United Kingdom and Sweden. A steering committee was established to shape the Index, establish indicators and evaluate progress.

The Index was launched on World Psoriasis Day, October 29th and included:

- A preview webinar to present the Index to supporters and contributors, organized on October 20th
- A launch event on October 29th, organized during the European Academy of Dermatology and Venereology Congress
- A social media campaign, press release, presentation deck, executive summary, and video
- An article published on the NCD Alliance blog

The High Lantern Group continued as consultants for IFPA for the Coalition during 2020, powering the Coalitions activities. More information about the Global Psoriasis Coalition is available on www.globalpsoriasiscoalition.com and @psocoalition on Twitter.

IFPA representatives have taken part in the official delegation of the Global Health Council to both sessions of the 73rd World Health Assembly. A report with key learnings from the 73rd World Health Assembly was shared with the membership. Moreover, IFPA followed the United Nations General Assembly and contributed to the language of the omnibus resolution through the process coordinated by the NCD Alliance. To explore opportunities for advocacy in Asia, IFPA participated to the annual meeting of the professional society for health economics and outcome research (ISPOR) for the Asia-Pacific region.

As accurate data and adaptation of terminology are emerging on the global level, IFPA established an internal unit, the policy unit, to align terminology to the current landscape. The policy unit worked on a number of issues during 2020. From the shift in communication strategy on the burden of psoriasis in light of the prevalence provided by the Global Psoriasis





Atlas, to the terminology to adopt around health care providers, to the definition of psoriatic disease.

IFPA's network in advocacy

IFPA renewed its collaboration with the NCD Alliance, the International Alliance of Patients' Organizations (IAPO), the Global Health Council, the International Alliance of Dermatology Patient Organizations (IADPO/Global Skin) IFPA is also a member of the Civil Society Engagement Mechanism for Universal Health Coverage (CSEM). IFPA is an active member of the Inclusive Agenda program of the NCD Alliance, a project promoting inclusivity in the non-communicable disease sphere. IFPA contributed with an article on world psoriasis day and one blog post on the Index on NCD Alliance platforms. IFPA participated to the two sessions of the 73rd World Health Assembly as part of the Global Health Council delegation, as well as a roundtable with the Director General of the World Health Organization organized by the Global Health Council.

At the end of 2019 IFPA decided to participate in a global information campaign "Turning the Tide" about non-communicable diseases together with NCD Alliance and BBC StoryWorks. Turning the Tide is a series of short films about the bold actions being carried out by communities and organizations to take on NCDs. The stories are about the small and significant changes being made for better, healthier lives. The release of the project was early 2020, with psoriasis highlighted in IFPA's film "More than Skin Deep". The purpose was to highlight that the burden of psoriasis goes deeper than the skin and impact physical, mental, and economic wellbeing. The film challenges the idea of treating non-communicable diseases in silos and it also offer solutions.

Science

The Global Psoriasis Atlas (GPA)

The Global Psoriasis Atlas is an international project launched in 2016 by IFPA, International League of Dermatological Societies (ILDs) and the International Psoriasis Council (IPC). It

has made incredible progress and is delivered by global experts and an academic project team led by the University of Manchester. The vision is that the GPA will become the leading epidemiological resource globally on psoriasis and psoriatic arthritis providing the common benchmark on the burden of psoriasis in all countries and regions throughout the world. The Atlas will seek to: drive continuous improvement in understanding the natural history of psoriasis; uncover how it affects the individual and society; understand how healthcare can be improved for those living with the disease.

The GPA launched the first-ever comprehensive online database tool on World Psoriasis Day in October 2019. The epidemiological resource which is now available online contains data on the number of psoriasis cases, healthcare data and looks in depth at the experiences and faces behind people living with psoriasis. IFPA members contributed to the online database by sharing their stories during the 2019 annual members meeting and their experiences are featured on the GPA website.





In 2020 the GPA:

- Launched Phase II (2020-2023) for the research program, addressing existing knowledge gaps on: Epidemiology; Improving Diagnosis; Comorbid Disease; and the Economic Impact of Psoriasis.
- Added more regional coordinators and introduced national coordinators to the global research team.
- Published the world's largest systemic review of global data on the burden of psoriasis in the British Medical Journal.
- Achieved 3 additional publications on the co-morbid burden of psoriasis.
- The coordinators presented some of the latest research work for the year at IFPA Members Meetings held towards the end of the year.
- Despite the pandemic, the bi-annual meetings board and committee meetings were held virtually in April and October 2020.

Further information is available on www.globalpsoriasisatlas.org.

PsoProtect & PsoProtectMe

At the beginning of the COVID-19 pandemic, IFPA partnered with PsoProtect to investigate how people living with psoriasis are affected by COVID-19. By collecting both healthcare records and self-reported data, the team at PsoProtect can analyze many facets of the pandemic's impact, including outcomes of COVID-19 in people who have psoriasis, the mental health burden of living through the pandemic, and psoriasis flares because of stress or reduced access to treatment. IFPA and other organizations will be able to use these results to advocate for better provisions for people living with psoriatic disease through this pandemic and in future crises.

Contribution to Treatment Guidelines: European Centre for Dermatology

Treatment guidelines are an essential tool to improve quality of care for people with psoriasis. Many countries lack specific guidelines or protocols on the care and management of psoriasis. Representatives from IFPA were invited to participate in the consensus meetings for the European Centre for Guidelines Development led by the European

Dermatological Forum. Many patients have limited time with their HealthCare Provider, which may negatively impact the quality of care. In collaboration and support from the Dermatology experts, a patient guide was developed to introduce patients to the new treatment guide published in July 2020. A patient checklist was published alongside the guidelines.

External meetings

IFPA was represented at several meetings, summits and conferences as relevant to IFPA's mission and where of importance for IFPA to be represented, to participate and to build relationships. Highlights include:





Global NCD Alliance Forum, February 9-11

Global NCD Alliance forum took place in Sharjah, organized by IFPA's partner, the NCD Alliance. Board member Josef de Guzman represented IFPA at the meeting. De Guzman spoke at the Coalition building session and participated in the launch event for the BBC series "Turning the Tide" featuring IFPA's film "More than skin deep."

73rd World Health Assembly, May 18-19

IFPA representatives took part in the official delegation of the Global Health Council attending both sessions of the 73rd World Health Assembly (WHA), begun in May and resumed in November. A report with key learnings from the event was shared with IFPA membership. IFPA used the Resolution on COVID-19 Response adopted at the WHA to create a toolkit. The document guides patient associations in advocating for people with psoriatic disease during the COVID-19 pandemic.

EULAR Congress, June 3 - 6

In 2020, the European League Against Rheumatism (EULAR) Congress was held as an online event. IFPA followed the virtual sessions live, hearing latest updates on new treatment options for psoriatic arthritis. In addition, sessions addressed the risk of comorbidities like cardiovascular disease, diabetes, and metabolic syndrome among people living with psoriatic arthritis.

GRAPPA Annual Meeting, July 9 - 11

The Group for Research of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting was also held in a virtual format in 2020. IFPA was invited to attend GRAPPA's annual meeting and IDEOM's side-meeting. The meetings highlighted some of the most important developments at GRAPPA in the past year. Topics included COVID-19, outcome measures for musculoskeletal symptoms in psoriasis, trainee work, pustular psoriasis, related rheumatologic diseases, and composite measures.

74th United Nations General Assembly, September 22 - 25

IFPA followed the United Nations General Assembly and contributed to the language of the omnibus resolution through a process coordinated by the NCD Alliance. IFPA further participated in a roundtable with the Dr. Tedros, Director General of the World Health Organization, organized by the Global Health Council.

IDEOM Annual Meeting, October 23 - 24

The International Dermatology Outcome Measures (IDEOM) Annual Meeting began with a pre-meeting for Patient Research Partners. The networking session was attended by over 30 participants joined the event; among these, 25 were from the psoriasis community. This was followed by a two-day series of workshops and working group discussions in multiple disease areas including psoriasis and psoriatic arthritis.

EADV Congress, October 29 - 31

The dates of the European Academy of Dermatology and Venereology (EADV) Congress 2020 coincided with World Psoriasis Day. IFPA created a booth to bring attention to World Psoriasis Day and our cause. At the scientific meetings, there were key presentations in





psoriasis care such as developments in biologics, biosimilars, and early findings on the impact of COVID-19 in people with psoriasis (presented by PsoProtect). Most importantly, it was evident that through advocacy efforts, patients' voices have been heard. Physicians and experts are more and more keen to connect psoriasis with comorbidities in multidisciplinary care.

WHO Informal Consultation on People living with NCDs, December 9-11

IFPA was invited to the 3-day digital meeting organized by the World Health Organization to involve people living with all NCDs in building an agenda that includes lived experiences. IFPA representatives actively participated in discussions. IFPA Board member Silvia Fernandez Barrio facilitated two sessions: Exploring Meaningful Engagement and Mapping the Way Forward.

Members

By end of 2020, IFPA had 62 regional, national, and associate members, in 55 countries.

Member Meetings 2020

In 2019, following dialogue at the IFPA Members Meeting in July, the Board decided to adopt a regional member meeting methodology for each third year (beginning 2020) on trial basis as an alternative to each year's global members meeting, in order to follow up on regional development potential.

IFPA organized four regional meetings for members in Pan America, Africa, Europe and Asia Pacific. Almost 150 participants joined the four member meetings hosted during 2020.

Each year the IFPA Member meetings are special, during 2020 the meetings provided many firsts:

- First time hosting regional meetings instead of one global meeting.
- First time hosting four member meetings in one year.
- First time hosting virtual member meetings.
- First time working with a conference platform.
- First time working with live translators.

The member meetings covered topics like updates from the Global Psoriasis Atlas, PsoProtect and their work on psoriasis and COVID-19, Health Technology Assessment and how it can empower patient advocates, as well as offering models of how to structure multiple level coalitions. We were also treated to excellent presentations from many IFPA Members who shared examples and successes from all the impressive work that had been done nationally during the year.

These meetings, which had been envisioned to be physical meetings starting a few months into the year, had to be transformed to virtual sessions given COVID-19 impact. It was also





shifted towards the end of the year to allow member associations to focus on their national needs during pandemic conditions. IFPA regional member meetings 2020 took place between November 21st and December 8th. In the Pan-American meeting IFPA provided interpreters in Spanish/English, which made the meeting more inclusive.

Member survey

IFPA's Member Survey is sent out annually to all IFPA Members. The member survey is conducted to gain a better understanding of member priorities, areas that may need further support from IFPA and overall satisfaction with IFPA as a federation. The responses collected through the survey are used for planning future activities and programs for members. In late 2020 as a follow-up on the survey, IFPA Members were also invited to participate in individual calls with IFPA staff, providing opportunity to discuss feedback and suggestions more extensively.

Results of the survey:

- A vast majority (87,5%) of IFPA Members rated their IFPA Membership as Very Good or Excellent.
- A majority (66%) of IFPA Members responded that they felt the value of their IFPA Membership had increased during the past years.
- One fourth (25%) of members felt the value of their membership had stayed the same, and 9% were undecided or felt the value had decreased.

More details from the member survey can be found in the "IFPA Member Survey 2020" report.

Capacity development

Through IFPA's Capacity Development Program, a number of activities were organized for IFPA members:

Webinars

The webinar series continued during 2020, starting with a kick-off webinar in the beginning of the year to provide an overview of IFPA's planned operations for 2020.

The team behind the PsoProtect and PsoProtectMe surveys joined for a webinar titled "PsoProtect: Understanding how covid-19 affects people living with psoriasis".

IFPA was fortunate to have Dr. April Armstrong hosting hold a presentation on Psoriasis and its comorbidities, a topic that has been highly requested by IFPA Members.

International Alliance of Patients' Organizations CEO, Kawaldip Sehmi, led an interesting discussion on the importance of patient safety, the newly adopted WHA resolution 'Global action on patient safety' and how patient advocates can use it in their work.

As part of the preparations ahead of World Psoriasis Day, two virtual meetings for IFPA Members and Sponsors were held.





Mentorship program

In March, IFPA launched a new mentorship program as part of Capacity Building efforts withing the psoriasis community.

The mentorship initiative was designed as part of IFPA's expansion effort to extend the capacity and reach of the Psoriasis and Psoriatic Arthritis community. Individuals in the process of starting new patient associations for people living with psoriasis and/or psoriatic arthritis are matched with a mentor from one of IFPA's already established member associations. The mentorship initiative aims to support newly formed psoriasis and/or psoriatic arthritis associations. At the end of 2020, individuals from Belarus, Ghana, India, Namibia, Nepal, and Tunisia were actively participating in the mentorship program to get support in starting and building new patient associations. This program offers IFPA members and individuals from newly formed associations a mutually beneficial opportunity to share ideas and experiences. The mentorship brought value for both mentors and mentees during 2020 and activities will continue during 2021.

Coaching Program

The coaching program was first announced in 2020. Matching of applicants will start early 2021. It encourages and supports knowledge exchange within IFPA. Individuals from IFPA member organizations that possess skills that could be useful for other members can apply to be coaches. Individuals from IFPA member organizations that wish to expand their knowledge or build skills in a specific area can apply to receive coaching. This program offers IFPA members a mutually beneficial opportunity to share skills and experiences and leads to a more connected federation.

World Psoriasis Day

World Psoriasis Day (WPD) is an annual day dedicated to people living with psoriasis and psoriatic arthritis, celebrated on October 29th. The overall aim of WPD is to:

- Raise awareness on the severity of the disease and on the everyday challenges faced by people living with psoriasis and psoriatic arthritis.
- Spread information about psoriasis, refute common misconceptions and increase patients' knowledge.
- Improve access to treatment by targeting health ministers, governments and decision-makers.
- Give the psoriasis community a voice, to empower people living with psoriasis.

The theme of 2020 was INFORMED, the second year in a three-year campaign (Connected, Informed, United). IFPA developed the campaign, with the purpose to emphasize the importance of credible, abundant, and new information about psoriasis and psoriatic arthritis. Informed individuals can manage their psoriasis better, and motivate behavior change in their communities. In the same way, informed patient associations, advocates, medical professionals, and scientists are more effective in their work. People living with these chronic inflammatory illnesses are further burdened by having to sift through unreliable, and sometimes predatory information before arriving at reliable resources that





can truly help. IFPA and its members are devoted to making the journey simpler. Good information is a support for everyone.

What no one knew when designing the 2020 campaign was the arrival of the COVID-19 pandemic. Uncertainty about the possible impact of COVID-19 on people living with psoriasis and psoriatic arthritis highlighted the urgency of reliable, helpful information. Lockdowns and isolation orders changed the shape of the regular World Psoriasis Day activities. Grief and anxiety made mental health burdens heavier. At the same time, IFPA and its members discovered new opportunities to maximize World Psoriasis Day. The campaign was transformed into a digital one, which allowed global connecting more than ever. Webinars, videos, infographics, websites, and apps offered beautiful solutions to transmit the information praised. In the end, the global campaign was changed, and in many ways enhanced by the special circumstances. IFPA's message was heard.

Some activities held by IFPA member associations included:

- Online dance parties in the Philippines
- Polka dot dress-up in Czech Republic
- Face-to-face meetings and virtual webinars in Kenya

Notably, this year's World Psoriasis Day campaign was celebrated by many external parties. Following efforts to make World Psoriasis Day more accessible, it seems that private individuals, non-profit organizations, industry stakeholders, advocacy groups, and governmental bodies all included World Psoriasis Day on their calendars. They engaged with IFPA's website, toolkit, and theme document to actively participate in the campaign. It is a new outcome that increased the reach of the message by an estimated three-fold. IFPA look forward to building upon this success in next year's UNITED campaign.

Some of the highlights of the campaign:

- 43,8 M people reached on social media
- 102 countries participated online in the global campaign
- 15 national monuments lighted orange in honor of World Psoriasis Day
- 1,1 K downloads of the World Psoriasis Day Toolkit

See more results from the campaign in the World Psoriasis Day Report!

COVID-19 response

In the beginning of March IFPA activated a COVID-19 task force to deliver helpful and targeted information to people living with psoriasis and psoriatic arthritis during the pandemic. IFPA published statements and answers to many frequently asked questions. At the same time IFPA suspended physical meetings and travel until further notice. A set of COVID-19 webpages was created on the IFPA website to share guidance, and link to resources around the world. In April IFPA partnered with PsoProtect to gather statistical information about the impact of COVID-19 on people with psoriasis. The PsoProtect registry for healthcare providers has already yielded interesting findings to start to answer





one of the most worrying questions: Does having psoriasis make one more vulnerable to COVID-19? From May IFPA started campaigning for the PsoProtectMe survey, encouraging anyone living with psoriasis to report their experience during COVID-19. It has helped to understand the behaviors and strategies that people with psoriasis are using to protect themselves during the pandemic, and responses are continuously collected. In June IFPA's Global Psoriasis Coalition released a statement on COVID-19 and published an advocacy toolkit titled "Together we will overcome" to guide patient organizations in using the WHA Resolution on COVID-19 Response to advocate for people with psoriatic disease during the pandemic.

People living with chronic illnesses must be able to access continued care, even during a pandemic. In October, IFPA incorporated COVID-19 into the World Psoriasis Day theme, "Be Informed". The COVID-19 pandemic highlights the absolute necessity for complete, reliable information on psoriatic disease. Together, IFPA, PsoProtect and the Global Psoriasis Atlas collect patient testimonies, putting human faces and voices to the experience of living with psoriasis during the pandemic. In December, IFPA published a joint statement regarding the safety and effectiveness of COVID-19 vaccines for people with psoriatic disease.

Communications

2020 communications were heavily impacted by COVID-19. Pandemic restrictions changed the way to work and allowed for exploration of new methods to connect with IFPA's audience. IFPA adopted new digital tools, made opportunities to connect more personally with its members, and built strategies to spread reliable information. These augmented the standard communications goals for 2020.

This year analysis was emphasized. IFPA collected data to understand how its message was spreading and where it could become more effective. Prioritizing the three most frequented communications channels (social media, newsletters, and the IFPA website), IFPA established tools like Hootsuite, Mail Chimp, and Google Analytics for data collection.

In 2020, IFPA launched the IFPA update, an internal newsletter to communicate more frequently with IFPA members and keep them informed of developing projects and opportunities.

IFPA sent four Quarterly Newsletters to members, stakeholders, and partners. These illuminated such topics as the psoriatic disease community's response to COVID-19, World Psoriasis Day, Executive Director Frida Dunger Johnsson's arrival at IFPA, and IFPA's actions in 2020.

During 2020 IFPA's YouTube and LinkedIn pages were revived! Check them out to see activity from World Psoriasis Day and beyond!





The theme of World Psoriasis Day 2020 was Be Informed. In honor of this theme, IFPA implemented a series of quarterly informational social media campaigns throughout 2020. Topics included mental health and psoriatic disease, the burden of psoriatic arthritis, and personal testimonies. On World Psoriasis Day the IFPA Instagram account gained its 1,000th follower.

IFPA website in numbers

- Users in 2020: 25,726
- Page views in 2020: 63,344
- Top 4 countries frequenting the IFPA website in 2020: USA, India, Indonesia, and UK
- Top 5 webpages visited in 2020
 - Homepage: 12,079
 - World Psoriasis Day: 8,227
 - World Psoriasis Day 2020: 6,889
 - Our Cause: 3,652
 - Our Members: 2,578

2020 top post on Facebook was February 18th Psoriasis is more than skin deep. #TurningTheTide: 16 557 reactions.

By end of 2020, IFPA had 14K Facebook followers, 6,5K Twitter followers, 1,1K followers on Instagram and modest 158 LinkedIn followers.

One silver lining from the pandemic has been the opportunity to connect more frequently and closely with IFPA members through video chats and virtual meetings.

The 6th IFPA World Psoriasis and Psoriatic Arthritis Conference in 2021

IFPA has been organizing the World Psoriasis and Psoriatic Arthritis conference since the first meeting was held in Stockholm in 2006.

With input from dermatologists, rheumatologists, allied health professionals and patient leaders, the purpose of the Conference is to improve the understanding and implementation related to psoriatic disease while providing a platform to discuss the latest developments in treatment and care.

Since its inception the conference has grown from a participation of 650 delegates from 47 countries to over 1200 delegates from 70 countries. The Conference consists of two programs:

- The scientific program with patient focus.
- A complementary program for allied professionals, non-specialists and patient leaders.





In 2020, IFPA continued with the preparations ahead of the 6th IFPA World Psoriasis and Psoriatic Arthritis Conference. Due to COVID-19 impact the Conference is now planned to be a fully virtual conference, which will take place as a fully virtual event June 30th – July 3rd, 2021. The conference programs for 2021 have been influenced by suggestions from IFPA members regarding initial themes and overall key topics. The IFPA Board met in early 2020 with IFPA's conference bureau team and Scientific Executive Committee to plan for the Conference. IFPA's conference was promoted widely on various virtual platforms at both regional levels and at international meetings including the EADV Virtual Meeting 2020, national Psoriasis and Psoriatic Virtual Conference Congress led by Psoriasis Philippines and through direct email marketing campaigns, scientific journals and websites.

The theme of the upcoming conference is “*CONNECTED, INFORMED and UNITED to improve multidisciplinary care for people with psoriasis and psoriatic arthritis*”.

Further information is available on www.ifpaworldconference.com.

Corporate partners

As part of the IFPA Partnership Program, IFPA has received support in 2020 from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, LEO Pharma, Lilly, Novartis, Pfizer and UCB.

Support for the Global Psoriasis Coalition was provided by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, LEO Pharma, Novartis, and UCB.

In 2020, the Psoriatic Disease Response Index project, initialized in 2019, was finalized and support was provided by AbbVie, Bristol-Myers Squibb, Celgene, Janssen, LEO Pharma and Novartis.

IFPA has also collaborated separately with numerous corporate partners in various projects and initiatives to provide additional value for people living with psoriasis and psoriatic arthritis.

Overall summary of 2020

The year of INFORMED. The year of COVID-19.

2020 challenged IFPA to change plans, grow closer to its members, and develop strategies for resilience. Uncertainty surrounding the pandemic highlighted the necessity for credible, complete information about psoriasis and psoriatic arthritis. As the need for answers grew, IFPA responded to the uncertainty with the World Psoriasis Day campaign: Be Informed. As the pandemic continued, IFPA sharpened its demands. People with psoriasis and psoriatic arthritis must be included in emergency provisions. Health systems must be prepared to ensure adequate care for people with chronic illnesses, even during a crisis. IFPA called for more support at the World Health Assembly and the United Nations General Assembly. IFPA adapted and pushed forward.





INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS

IFPA's development was also highlighted as IFPA was named International Association of the Year by the Association of Association Executives (AAE) in their International & European Association Awards 2020. Competing against 102 entries in 12 categories, IFPA earned the international title. The judges said, "The organization is doing everything an international federation of associations should do."

In November, the organization welcomed Frida Dunger Johnsson as Executive Director. IFPA's results for 2020 may not match the original plans, but the achievements exceeded expectations.





Administration report

The Board of the International Federation of Psoriasis Associations hereby delivers the annual accounts for the year 2020-01-01 to 2020-12-31.

Regarding the result and financial positions, please refer to the attached statements.



President
Hoseah Waweru, M.D.
Nairobi, Kenya



Vice President
Ingvar Ágúst Ingvarsson
Reykjavik, Iceland



Secretary
Leticia Lopez
San Juan, Puerto Rico



Treasurer
Josef de Guzman
Manila, Philippines



Member at Large
Kathleen Gallant
Pittsburgh, USA



Substitute
Silvia Fernandez Barrio
Buenos Aires, Argentina



Substitute
David Trigos Herraiz
Oviedo, Spain





International Federation of Psoriasis Associations (IFPA) Org. no 802428-5986

Profit and loss account

	2020-01-01 2020-12-31		2019-01-01 2019-12-31	
	SEK	EUR	SEK	EUR
Incomes		1,0375		10,4336
Membership fees	108 463	10 806	32426	3 108
Rounding- off to whole kronor	2	0	8	1
Boehringer-Ingelheim	782 408	77 949	349135	33 463
Janssen	1 311 971	130 707	0	0
AbbVie	430 475	42 887	260 614	24 978
Almirall S.A	0	0	522 780	50 105
LEO Pharma A/S	602 358	60 011	1 069 885	102 542
Bristol-Myers Squibb	1 199 182	119 470	1 172 182	112 347
UCB	689 032	68 646	1 050 600	100 694
Celgene	97 333	9 697	1 475 870	141 454
Novartis	980 383	97 672	1 536 514	147 266
Eli Lilly	546 951	54 491	736 792	70 617
Pfizer	702 625	70 000	751 394	72 017
Amgen	444 527	44 287	0	0
Total income	7 895 708	786 621	8 958 199	858 591



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS**Profit and loss account**2020-01-01
2020-12-312019-01-01
2019-12-31

Costs	SEK	EUR 1,0375	SEK	EUR 10,4336
Office rental agreement	-559 879	-55 779	-560 693	-53 739
Freight and transport	-18 707	-1 864	-756	-72
Conference costs	-355 008	-35 368	-1 476 405	-141 505
Tele meetings	0	0	-2 000	-192
Travel costs	-167 855	-16 723	-331 200	-31 744
Refund members	-36 984	-3 685	-69 349	-6 647
Hotel costs	-31 989	-3 187	-368 262	-35 296
Food	-12 300	-1 225	-63 976	-6 132
Reimbursement	-39 204	-3 906	-610 396	-58 503
Printing costs	-43 060	-4 290	-57 656	-5 526
PR-Marketing	-34 877	-3 475	-287 599	-27 565
Entertainment	-2 205	-220	-19 545	-1 873
Gifts	-3 600	-359	-8 400	-805
Office material	-96 641	-9 628	-124 095	-11 894
Phone	-62 448	-6 221	-65 234	-6 252
Insurance for the organization	-14 612	-1 456	-11 453	-1 098
Accountant and audit	-353 297	-35 198	-241 142	-23 112
Consultants	-3 150 413	-313 864	-2 547 952	-244 206
Web	-7 823	-779	-31 367	-3 006
IT-costs	-141 416	-14 089	0	0
News service	-20 625	-2 055	-28 935	-2 773
Bank fees	-9 945	-991	-8 805	-844
Membership fees	-267 163	-26 617	-243 548	-23 343
Subscriptions and articles	-21 744	-2 166	-93 125	-8 925
Other operating expenses	156 699	15 611	66 370	6 361
Interest taxes and fees	-1 027	-102	-1 130	-108
Staff costs	-5 044 565	-502 572	-4 068 248	-389 918
Exchange profit/loss	-95 893	-9 553	-147 804	-14 166
Total costs	-10 436 580	-1 039 759	-11 402 705	-1 092 883
Profit (+) / Loss (-)	-2 540 872	-253 138	-2 444 505	-234 292



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS

Costs per activity

	2020-01-01 2020-12-31		2019-01-01 2019-12-31	
	SEK	EUR 1,0375	SEK	EUR 10,4336
1. WPC				
Travel costs	-5 601	-558	-5 404	-518
Food	0	0	-40	-4
PR-Marketing	-17 839	-1 777	0	0
Consultants	-133 135	-13 264	-60 927	-5 839
Other operating expenses	156 699	15 611	66 370	6 361
Exchange profit/ loss	-124	-12	0	0
Total costs	0	0	0	0
2. World Psoriasis Day				
Freight and transport	-16 084	-1 602	0	0
Conference costs	0	0	-1 277 809	-122 471
Travel costs	0	0	-23 517	-2 254
Refund members	0	0	-20 114	-1 928
Food	0	0	-729	-70
Reimbursement	0	0	-238 590	-22 867
Printing costs	-43 060	-4 290	-21 894	-2 098
PR-Marketing	-15 942	-1 588	-10 573	-1 013
Office material	0	0	-6 838	-655
Consultants	-2 500	-249	-680 383	-65 211
Web	0	0	-21 042	-2 017
News service	0	0	-111	-11
Bank fee	0	0	-107	-10
Subscriptions and articles	0	0	-406	-39
Exchange profit/ loss	2 244	224	-6 222	-596
Total costs	-75 341	-7 506	-2 308 335	-221 240
4. EADV				
Conference costs	-101 328	-10 095	-19 964	-1 913
Travel costs	0	0	-49 550	-4 749
Hotel costs	0	0	-42 737	-4 096
Food	0	0	-6 405	-614
Reimbursement	0	0	-77 522	-7 430
Print costs information material	0	0	-406	-39
PR Marketing	0	0	-900	-86
Exchange profit/ loss	-597	-59	-0	0
Total costs	-101 925	-10 154	-197 484	-18 928



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS**Costs per activity**2020-01-01
2020-12-312019-01-01
2019-12-31

	SEK	EUR 1,0375	SEK	EUR 10,4336
5. External Meetings				
Conference costs	-2 244	-224	0	0
Travel costs	-40 040	-3 989	0	0
Food	-137	-14	0	0
Reimbursement	0	0	-15 879	-1 522
Entertainment	-1 600	-159	0	0
Exchange profit/loss	218	22	0	0
Total costs	-43 804	- 4 364	-15 879	-1 522

6. EC Meetings				
Conference costs	0	0	-38 333	-3 674
Travel costs	-75 593	-7 531	0	0
Hotel costs	-26 750	-2 665	0	0
Food	-6 248	-622	0	0
Reimbursement	-23 661	-2 357	-24 032	-2 303
Total costs	-132 252	-13 176	-62 365	-5 977

8. Advocacy				
Travel costs	-5 054	-503	-33 996	-3 528
Hotel costs	-5 240	-522	-52 354	-5 018
Food	0	0	-6 192	-593
Reimbursement	-4 968	-495	-62 507	-5 991
Print costs information material	0	0	-4 856	-465
PR marketing	0	0	-274 126	-26 273
Entertainment	0	0	-19 436	-1 863
Bank fee	0	0	-91	-9
Membership fees	-264 706	-26 372	-241 090	-23 107
Exchange profit/ loss	-21 442	-2 136	-3 574	-343
Total costs	-301 409	-30 028	-698 222	-66 921



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS**Costs per activity**

	2020-01-01 2020-12-31	EUR 1,0375	2019-01-01 2019-12-31	EUR 10,4336
10. IFPA				
Office rental agreement	-559 879	-55 779	-560 693	-53 739
Freight and transport	-2 623	-261	-756	-72
Conference costs	-245 050	-24 413	-110 308	-10 572
Tele meetings	0	0	-2 000	-192
Travel costs	-41 568	-4 141	-218 734	-20 964
Refund members	-36 984	-3 685	-49 235	-4 719
Hotel costs	0	0	-273 170	-26 182
Food	-5 915	-589	-50 610	-4 851
Reimbursement	-10 574	-1 053	-180 296	-17 280
Printing costs	0	0	-13 831	-1 326
PR-Marketing	-1 097	-109	-2 000	-192
Entertainment	-605	-60	-109	-10
Gifts	-3 600	-359	-8 400	-805
Office material	-96 641	-9 628	-117 258	-11 238
Phone	-62 448	-6 221	-65 234	-6 252
Insurance for the organization	-14 612	-1 456	-11 453	-1 098
Accountant and audit	-353 297	-35 198	-241 142	-23 112
Consultants	-314 800	-31 362	-325 212	-31 170
Web	-7 823	-779	-10 326	-990
IT-costs	-141 416	-14 089	0	0
News service	-20 625	-2 055	-28 875	-2 768
Bank fees	-9 945	-991	-8 608	-825
Membership fees	-2 457	-245	-2 457	-236
Subscription and articles	-21 744	-2 166	-92 719	-8 887
Staff costs	-5 044 565	-502 572	-4 068 248	-389 918
Interest expenses for taxes and fees	-1 027	-102	-1 079	-103
Exchange profit/loss	-73 128	-7 285	-78 436	-7 518
	-7 072 422	-704 600	-6 521 189	-625 018

13. Global Psoriasis Coalition				
Conference costs	-6 385	-636	-29 991	-2 874
Reimbursement	0	0	-11 569	-1 109
Printing costs	0	0	-16 669	-1 598
Consultants	-1 487 314	-148 176	-992 844	-95 158
Exchange profit/loss	-1 223	-122	-47 509	-4 553
Total costs	-1 494 922	-148 934	-1 098 581	-105 293





INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS

Costs per activity

	2020-01-01 2020-12-31		2019-01-01 2019-12-31	
	SEK	EUR 1,0375	SEK	EUR 10,4336
15. Psoriasis Readiness Index				
Consultants	-1 212 664	-120 813	-488 586	-46 828
Exchange profit/loss	-1 840	-183	-12 063	-1 156
Total costs	-1 214 504	-120 997	-500 649	-47 984

These cost centers did not have any costs year 2020 and 2019:

07. Psoriasis Atlas

09. Under the spotlight

12. IFPA Solidarity Fund



Balance sheet

		2020-01-01 2020-12-31	EUR 10,0375	2019-01-01 2019-12-31	EUR 10,4336
	Note	SEK		SEK	
Bank assets and claims					
Outstanding claims	1	1 427 181	142 185	2 472 203	236 946
Other claims		2 890	288	2	0
Prepaid expenses and accrued income	2	1 846 021	183 912	294 930	28 267
Cash		2 262	225	2 153	206
PayPal		1 494	149	0	0
Bank Nordea		3 809 010	379 478	8 128 397	779 060
		7 088 857	706 237	10 897 684	1 044 480
Total bank assets and claims					

		2020-01-01 2020-12-31	EUR 10,0375	2019-01-01 2019-12-31	EUR 10,4336
	Note	SEK		SEK	
Capitals and creditors					
Capital		6 083 322	606 059	8 527 827	817 343
Profit or loss		-2 540 872	-253 138	-2 444 505	-234 292
Outstanding debts		213 508	21 271	1 286 059	123 261
Other debts		1 181 542	117 713	864 645	82 871
Prepaid income	3	2 024 428	201 687	1 997 723	191 470
Accrued expenses and fee paid in advance	4	126 928	12 645	665 934	63 826
					1 044 480
Total capital and creditors		7 088 857	706 237	10 897 684	480



Notes

2020-01-01
2020-12-31

2019-01-01
2019-12-31

	SEK	EUR	SEK	EUR
		10,0375		10,4336

Note 1 Outstanding claims

Pfizer	0	0	751 394	72 017
UCB	715 589	70 000	1 720 809	164 930
The Interregional Charitable Pub. Org. Skin and Allergic Diseases	506	50	0	0
Novartis	2 000	199	0	0
Bristol Myers Squibb	709 086	70 000	0	0
Total	1 427 181	140 250	2 472 203	236 946

Note 2 Prepaid expenses and accrued income

Söderberg & Partners Insurance Consulting AB	1 250	125	0	0
Alviks Strand kontorshotell	135 533	13 503	131 530	12 606
Arén & Partner	0	0	862	83
International Alliance of Patients of Psoriasis	0	0	2 457	236
Fortnox AB	1 765	176	1 865	179
Europeiska ERV	7 500	747	7 500	719
Newsmachine Business Intelligence NMBI AB	0	0	20 625	1 977
Scrive	2 063	205	0	0
Prepaid cost WPC	223 069	22 224	66 370	6 361
Prepaid membership fee GHC 2021	9 807	977	0	0
<i>Accrued Income</i>			0	0
Accrued income AbbVie	0	0	63 720	6 107
Accrued income Pfizer	702 625	70 000	0	0
Accrued income Boehringer Ingelheim	433 274	43 166	0	0
Accrued income UCB	331 238	33 000	0	0
Accrued membership fees	7 829	780	0	0
Credit card costs, not yet invoiced	-9 932	-989	0	0
Total	1 846 021	183 912	294 930	28 267



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS

Note 3 Prepaid income	2020-01-01 2020-12-31		2019-01-01 2019-12-31	
	SEK	EUR 10,0375	SEK	EUR 10,4336
AbbVie	0	0	260 614	24 978
Bristol Myers Squibb	1 044 297	104 040	1 199 182	114 935
UCB	357 795	35 646	0	0
Boehringer Ingelheim	0	0	349 135	33 463
Celgene	0	0	97 333	9 329
Novartis	0	0	91 460	8 766
Amgen	622 337	62 001	0	0
Total	2 024 428	201 687	1 997 723	191 470

Note 4 Accrued costs and fees paid in advance

Hummelkläppen, auditor	92 930	9 258	60 000	5 751
Grant Thornton	23 565	2 348	0	0
Accrued reimbursement Global Skin 2019	10 433	1 000	10 433	1 000
Accrued expenses Patrik Vuorio 2018 & 2019	0	0	221 514	21 231
Accrued reimbursement Turkey 2018	0	0	2 636	253
Accrued cost BBC	0	0	274 126	26 273
Accrued reimbursement Hoseah Waweru 2019	0	0	39 013	3 739
Accrued reimbursement Puerto Rico AAD 2019	0	0	9 913	950
Accrued reimbursement David Trigos 2019	0	0	9 497	910
Accrued reimbursement Israel 2019	0	0	6 458	619
Accrued reimbursement Kenya 2019	0	0	10 433	1 000
Accrued reimbursement USA 2019	0	0	10 433	1 000
Accrued reimbursement Panama 2019	0	0	11 477	1 100
Total	126 928	12 606	665 934	63 826





INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS

Date of signing: 2021-06-15

Hoseah Waweru
President

Ingvar Ingvarsson
Vice President

Leticia Lopez
Secretary

Josef de Guzman
Treasurer

Kathleen Gallant
Member-at-Large

Tommy Nilsson
Authorized Public Accountant



Verification

Transaction 09222115557448639558

Document

IFPA Annual Accounts 2020_final

Main document

27 pages

Initiated on 2021-06-15 11:51:59 CEST (+0200) by Ida Mourujärvi (IM)

Finalised on 2021-06-18 11:57:06 CEST (+0200)

Initiator

Ida Mourujärvi (IM)

IFPA International Federation of Psoriasis Associations

ida.mourujarvi@ifpa-pso.com

Signing parties

Hoseah Waweru (HW)

IFPA

hoseah.waweru@ifpa-pso.com



Signed 2021-06-15 20:22:19 CEST (+0200)

Ingvar Ingvarsson (II)

IFPA

ingvar.ingvarsson@ifpa-pso.com



Signed 2021-06-15 16:50:14 CEST (+0200)

Leticia Lopez (LL)

IFPA

leticia.lopez@ifpa-pso.com



Signed 2021-06-15 12:59:23 CEST (+0200)

Josef de Guzman (JdG)

IFPA

josef.deguzman@ifpa-pso.com



Signed 2021-06-17 17:30:25 CEST (+0200)

Kathleen Gallant (KG)

IFPA

kathleen.gallant@ifpa-pso.com



Signed 2021-06-15 12:51:22 CEST (+0200)

Tommy Nilsson (TN)

Hummelkläppen i Stockholm AB

tommy.nilsson@hummelklappen.se



Signed 2021-06-18 11:57:06 CEST (+0200)

This verification was issued by Scrive. Information in italics has been safely verified by Scrive. For more



Verification

Transaction 09222115557448639558

information/evidence about this document see the concealed attachments. Use a PDF-reader such as Adobe Reader that can show concealed attachments to view the attachments. Please observe that if the document is printed, the integrity of such printed copy cannot be verified as per the below and that a basic print-out lacks the contents of the concealed attachments. The digital signature (electronic seal) ensures that the integrity of this document, including the concealed attachments, can be proven mathematically and independently of Scrive. For your convenience Scrive also provides a service that enables you to automatically verify the document's integrity at: <https://scrive.com/verify>





Translation of Auditor's Report

To the meeting of the General Assembly of its Full members of International Federation of Psoriasis Associations

Corporate identity number 802428-5986

Report on the annual accounts

Opinions

I have audited the annual accounts of International Federation of Psoriasis Associations for the financial year 2020.

In my opinion, the annual accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of International Federation of Psoriasis Associations as of 31 december 2020 and its financial performance for the year then ended in accordance with the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts.

I therefore recommend that the general meeting of members adopts the income statement and balance sheet.

Basis for Opinions

I conducted my audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. My responsibilities under those standards are further described in the *Auditor's Responsibilities* section. I am independent of International Federation of Psoriasis Associations in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled my ethical responsibilities in accordance with these requirements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinions.

Responsibilities of the Board of Directors

The Board of Directors is responsible for the preparation of the annual accounts and that they give a fair presentation in accordance with the Annual Accounts Act. The Board of Directors is also responsible for such internal control as it determines is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts, The Board of Directors is responsible for the assessment of the company's ability to continue as a going concern. It discloses, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is not applied if decision has been taken to discontinue the operations.

Auditor's responsibility

My objectives are to obtain reasonable assurance about whether the annual accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts.

As part of an audit in accordance with ISAs, I exercise professional judgment and maintain professional skepticism throughout the audit. I also:

- Identify and assess the risks of material misstatement of the annual accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinions. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of the company's internal control relevant to my audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors .

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting in preparing the annual accounts. I also draw a conclusion, based on the audit evidence obtained, as to whether any material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the annual accounts or, if such disclosures are inadequate, to modify my opinion about the annual accounts. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the annual accounts, including the disclosures, and whether the annual accounts represent the underlying transactions and events in a manner that achieves fair presentation.

I must inform the Board of Directors of, among other matters, the planned scope and timing of the audit. I must also inform of significant audit findings during my audit, including any significant deficiencies in internal control that I identified.

Report on other legal and regulatory requirements

Opinions

In addition to my audit of the annual accounts, I have also audited the administration of the Board of Directors of International Federation of Psoriasis Associations for the financial year 2020 and the proposed appropriations of the company's profit or loss.

I recommend to the general meeting of members that the loss be dealt with in accordance with the proposal in the statutory administration report and that the of the Board of Directors be discharged from liability for the financial year.

Basis for Opinions

I conducted the audit in accordance with generally accepted auditing standards in Sweden. My responsibilities under those standards are further described in the *Auditor's Responsibilities* section. I am independent of International Federation of Psoriasis Associations in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled my ethical responsibilities in accordance with these requirements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinions.

Responsibilities of the Board of Directors

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's type of operations, size and risks place on the size of the company's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner.

***Auditor's responsibility***

My objective concerning the audit of the administration, and thereby my opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors in any material respect:


- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

My objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby my opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.

As part of an audit in accordance with generally accepted auditing standards in Sweden, I exercise professional judgment and maintain professional skepticism throughout the audit. The examination of the administration and the proposed appropriations of the company's profit or loss is based primarily on the audit of the accounts. Additional audit procedures performed are based on my professional judgment with starting point in risk and materiality. This means that I focus the examination on such actions, areas and relationships that are material for the operations and where deviations and violations would have particular importance for the company's situation. I examine and test decisions undertaken, support for decisions, actions taken and other circumstances that are relevant to my opinion concerning discharge from liability. As a basis for my opinion on the Board of Directors' proposed appropriations of the company's profit or loss I examined whether the proposal is in accordance with the Companies Act.

Stockholm 2021-06-18



Tommy Nilsson
Authorized Public Accountant